Business
Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive global licensing agreement with Celltrion Inc., a leading global biopharmaceutical company, for two of Kaigene's nonclinical-stage assets, KG006 and KG002.
About this update from Celltrion, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Celltrion will develop and commercialize Kaigene's nonclinical-stage antibody assets, KG006 and KG002, under an exclusive licensing agreement.","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Kaigene will receive $8M upfront payment and up to $736M in potential milestone payments, including $11M in near-term milestones through the initiation of Phase 1 study.","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":315,"olType":false},{"type":"text","content":"ROCKVILLE, Md., Nov. 3, 2025 /PRNewswire/ -- Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive global licensing agreement with Celltrion Inc., a leading global biopharmaceutical company, for two of Kaigene's nonclinical-stage assets, KG006 and KG002.","length":392,"tagName":"p"},{"type":"image","alt":"Kaigene","displaySize":"","headline":null,"caption":"Kaigene","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":132,"url":"https://media.zenfs.com/en/prnewswire.com/d8fbdbe004e6f74e6bd243fb48bafee8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J1PAJfMcc0oaEu4GTYl17Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d8fbdbe004e6f74e6bd243fb48bafee8","width":400,"height":132}},"href":"https://mma.prnewswire.com/media/2811727/Kaigene__Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the terms of the agreement, Kaigene will receive $8 million upfront payment and up to $736 million in total milestone payments, including $11 million in near-term milestones through the initiation of Phase 1 clinical trials. Kaigene is also eligible to receive tiered royalties on net sales if the product from the collaboration is commercialized. Celltrion will obtain exclusive rights to develop and commercialize KG006 worldwide except Greater China and Japan, and will hold worldwide rights for KG002.","length":511,"tagName":"p"},{"type":"text","content":""Kaigene is a discovery-driven biotech focused on creating innovative antibody therapeutics," said Minjae Shin, Chief Executive Officer of Kaigene Inc. "Our business model is to provide non-clinical antibod...